Congress took a giant step forward to reduce health disparities by expanding clinical trial access to more than 41.6 million Medicaid beneficiaries through passage of the bipartisan CLINICAL TREATMENT Act as part of its end-of-year legislative package. We commend Congress for passing this commonsense fix to increase the diversity of participants in clinical trials, improve the validity of clinical research, and help reduce disparities in treatment outcomes for people with life-threatening diseases—disparities that have only been magnified by the COVID-19 pandemic.
The American Society of Clinical Oncology (the Society), an affiliated organization of the Association for Clinical Oncology (the Association), collectively known as ASCO, submitted an amicus curiae brief in support of motions in four cases to enjoin the Most Favored Nation (MFN) Model from taking effect on January 1, 2021. The Society’s friend-of-the-court brief urges the courts to stop implementation of the model, citing its devastating impact on patients.
ASCO has elected Eric P. Winer, MD, FASCO, a long-time member and volunteer, to serve as its President for the term beginning in June 2022.
ASCO today issued comprehensive recommendations to guide the cancer community’s eventual recovery from the COVID-19 pandemic. By applying lessons learned during the pandemic, ASCO’s Road to Recovery Report: Learning from the COVID-19 Experience to Improve Clinical Research and Cancer Care intends to make cancer care and research opportunities more accessible to and equitable for patients in every community. Importantly, ASCO aims, with its recommendations, to address long-standing cancer care disparities that have been highlighted by the pandemic.
The Association for Clinical Oncology (ASCO) opposes the Most Favored Nation (MFN) Model for Medicare Part B drug reimbursement, which outlines a structured, nationwide, mandatory demonstration that will be phased in over four years, with full implementation for the final three years of the seven-year model. This plan effectively overrides a statutory provision under the guise of a demonstration project by imposing a new reimbursement model on cancer care absent any evidence that it can lower costs without negative consequences for Medicare beneficiaries.
Alexandria, VA — Julie R. Gralow, MD, FACP, FASCO, Professor of Medical Oncology and Director of Breast Medical Oncology at the University of Washington, Fred Hutchinson Cancer Research Center, and the Seattle Cancer Care Alliance, has been named Chief Medical Officer (CMO) of the American Society of Clinical Oncology (ASCO). She will succeed Dr. Richard Schilsky, who will retire in February 2021 after having served as ASCO’s CMO since 2013. Dr. Gralow is a highly respected leader in the field of clinical oncology with deep expertise in patient care, research, education, and global health. She will begin her new position on February 15, 2021.
As part of its ongoing commitment to addressing inequities in cancer care and research, the American Society of Clinical Oncology (ASCO) is launching a new educational series focused on the role of social determinants of health in cancer care and cancer outcomes.
Oncology providers familiar with the ASCO guideline on older adults with cancer are two to four times more likely to conduct a geriatric assessment on patients with cancer over the age of 65, according to the first international ASCO survey aimed at determining if and how often cancer providers are using geriatric assessments when treating older adults.
During the peak of the COVID-19 pandemic, fewer Black and Hispanic patients with cancer used telehealth (including phone encounters and video visits) as compared with white patients according to findings from an analysis of data from New York City hospitals. Significant disparities in the use of telehealth not only limit access to quality cancer care for these patients during the pandemic but will continue to hinder patient care as telehealth use becomes more integrated into standard cancer care. The study will be presented as part of the virtual 2020 ASCO Quality Care Symposium.
A study of more than 500 patients with cancer and COVID-19 at a large cancer center in Boston found that Black patients with cancer and COVID-19 were twice as likely to be hospitalized due to complications related to the virus as compared with white patients. Black patients were at greater risk of a visit to the emergency room. The findings will be presented at the upcoming virtual 2020 American Society of Clinical Oncology (ASCO) Quality Care Symposium.
The study will be presented at the American Society of Clinical Oncology’s (ASCO) upcoming Quality Care Symposium, taking place virtually October 9–10, 2020.
Two-thirds of Americans report that their scheduled cancer screenings, such as mammograms and colonoscopies, have been delayed or skipped in the midst of the COVID-19 crisis, according to the American Society of Clinical Oncology (ASCO)’s fourth annual National Cancer Opinion Survey.
ASCO applauds Senators Richard Burr (R-NC) and Ben Cardin (D-MD) for introducing bipartisan legislation to expand access to clinical trials and improve the quality of cancer research. The CLINICAL TREATMENT Act (S. 4742) would require Medicaid to guarantee coverage of the routine care costs of clinical trial participation for Medicaid enrollees with a life-threatening condition.
The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Carolyn Hendricks, MD, FASCO, for her exceptional contributions and commitment to the Association’s advocacy efforts.
The Association for Clinical Oncology (ASCO) today presented Representative Rosa DeLauro (CT-3) with the annual Congressional Champion for Cancer Care Award in recognition of her exceptional commitment to bipartisan support for cancer research and treatment. The award honors a Member of Congress who is a leading champion for patients and survivors of cancer, their families, and their cancer care teams.